A Phase 1-2 Study of AZD5492 in People With B-Cell Cancers

Full Title

A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium)

Purpose

Researchers want to find the best dose of AZD5492, a new type of immunotherapy, to treat people with B-cell cancers that keep growing after treatment. These cancers include:

• Large B-cell lymphoma
• Follicular lymphoma
• Mantle cell lymphoma
• Chronic lymphocytic leukemia/small lymphocytic leukemia

AZD5492 is called a T cell-engaging antibody. AZD5492 helps the immune system target and eliminate cancer cells.

Contact

For more information or to see if you can join this study, please call Dr. Lorenzo Falchi’s office at 646-608-3705.